SAN

82.86

-0.3%↓

UCB

266

+3.18%↑

SHL.DE

36.34

+0.78%↑

ARGX

639

+3.23%↑

VIE

33.29

+0.79%↑

SAN

82.86

-0.3%↓

UCB

266

+3.18%↑

SHL.DE

36.34

+0.78%↑

ARGX

639

+3.23%↑

VIE

33.29

+0.79%↑

SAN

82.86

-0.3%↓

UCB

266

+3.18%↑

SHL.DE

36.34

+0.78%↑

ARGX

639

+3.23%↑

VIE

33.29

+0.79%↑

SAN

82.86

-0.3%↓

UCB

266

+3.18%↑

SHL.DE

36.34

+0.78%↑

ARGX

639

+3.23%↑

VIE

33.29

+0.79%↑

SAN

82.86

-0.3%↓

UCB

266

+3.18%↑

SHL.DE

36.34

+0.78%↑

ARGX

639

+3.23%↑

VIE

33.29

+0.79%↑

Search

Almirall SA

Deschisă

SectorSănătate

12.26 1.16

Rezumat

Modificarea prețului

24h

Curent

Minim

12.02

Maxim

12.34

Indicatori cheie

By Trading Economics

Venit

-1.4M

20M

Vânzări

287M

548M

P/E

Medie Sector

60.7

56.063

Marjă de profit

3.575

Angajați

2,108

EBITDA

36M

102M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+16.09% upside

Dividende

By Dow Jones

Următoarele câștiguri

11 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-80M

2.6B

Deschiderea anterioară

11.1

Închiderea anterioară

12.26

Sentimentul știrilor

By Acuity

80%

20%

322 / 349 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Almirall SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 mar. 2026, 23:31 UTC

Acțiuni populare

Stocks to Watch: Nike, RH, NCino

31 mar. 2026, 22:35 UTC

Câștiguri

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr. 2026, 00:00 UTC

Achiziții, Fuziuni, Preluări

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar. 2026, 23:50 UTC

Achiziții, Fuziuni, Preluări

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar. 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar. 2026, 23:33 UTC

Market Talk
Evenimente importante

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar. 2026, 23:21 UTC

Câștiguri

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar. 2026, 23:14 UTC

Market Talk
Câștiguri

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar. 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Loss Widens >000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar. 2026, 21:46 UTC

Achiziții, Fuziuni, Preluări

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar. 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar. 2026, 21:33 UTC

Achiziții, Fuziuni, Preluări

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar. 2026, 21:33 UTC

Câștiguri

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar. 2026, 21:32 UTC

Câștiguri

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar. 2026, 21:28 UTC

Câștiguri

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar. 2026, 21:26 UTC

Câștiguri

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar. 2026, 21:25 UTC

Câștiguri

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar. 2026, 21:24 UTC

Market Talk
Câștiguri

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar. 2026, 21:22 UTC

Câștiguri

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar. 2026, 21:22 UTC

Câștiguri

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar. 2026, 21:21 UTC

Câștiguri

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar. 2026, 21:20 UTC

Câștiguri

Nike CEO: Converse Remains Important to Portfolio

Comparație

Modificare preț

Almirall SA Așteptări

Obiectiv de preț

By TipRanks

16.09% sus

Prognoză pe 12 luni

Medie 14.07 EUR  16.09%

Maxim 14.2 EUR

Minim 14 EUR

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAlmirall SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

1

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

9.76 / 10.2Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

322 / 349 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
help-icon Live chat